The KRAS G12C inhibitor field is evolving at a breakneck pace. While sotorasib set an initial benchmark response rate of ~30% (in combo), newer agents like oloramoracep are already demonstrating response rates exceeding 45%, rapidly resetting efficacy expectations and treatment standards for this population.

The DYNAMIC trial disappointingly showed that intensifying adjuvant chemotherapy for high-risk, ctDNA-positive stage 3 colorectal cancer patients does not improve outcomes. This suggests that for these tumors, underlying biology dictates recurrence more strongly than the aggressiveness of chemotherapy.

The STELLAR-303 trial is the first to show an immunotherapy-based regimen provides an overall survival benefit in microsatellite-stable CRC. Crucially, this benefit extends to patients with liver metastases, a subgroup that has historically shown profound resistance to immunotherapy, highlighting the drug's novel mechanism.

For HER2+ metastatic colorectal cancer, experts choose HER2-targeted therapies like TDXD or tucatinib/trastuzumab over standard second-line chemotherapy (FOLFIRI/BEV), despite label constraints. The rationale is the significantly higher response rate from targeting the oncogenic driver directly.

The practice-changing DYNAMIC trial showed that a ctDNA-guided strategy for stage II colorectal cancer reduces adjuvant chemotherapy use by 50%. Despite this significant de-escalation of treatment, patient outcomes and survival rates were identical to the standard-of-care approach.

Patient preference is a powerful force in oncology, with many actively seeking to avoid chemotherapy. In the Resolute 303 trial, patients overwhelmingly hope for the daraxoracib monotherapy arm, signaling a clear demand for effective, chemo-free regimens that will shape future clinical development.

For BRAF V600E mutated colorectal cancer, data argues against the common practice of starting with chemotherapy and saving targeted therapy for later. Hitting the specific tumor biology hard and early with combination targeted agents leads to significantly better outcomes, including doubling overall survival.

A common clinical pitfall is treating RAS/BRAF wild-type anal cancer with anti-EGFR antibodies, extrapolating from rectal adenocarcinoma protocols. Retrospective data shows this approach has only modest efficacy (4-5 month PFS) and is not a recommended strategy, highlighting a key difference between the two diseases.

The standard approach for first-line metastatic colorectal cancer is obsolete. Clinicians must test for and categorize patients into at least four, soon five, distinct biomarker-defined subgroups (MSI-high, BRAF V600E, RAS/RAF wild-type, HER2-positive, and the RAS-mutated "catch-all") to select the optimal initial therapy.